RE:RE:This is the drug Dr. Tardif has been investigating:Entering a New Era of Patient Care: Reducing Inflammation: Reducing inflammation is now an FDA approved path for cardiovascular disease potentially validating the path for CZO's avenanthramide which may also help manage glucose levels for diabetics, and aid in wound healing, etc.
"
LODOCO can reduce the risk of cardiac events in patients with established cardiovascular diseases by 31% on top of standard of care, will be available for prescription in the second half of 2023." "Entering a New Era of Patient Care
It has been long understood that inflammation as well as high cholesterol increases cardiovascular risks.
"Approval by the FDA of the first drug to target cardiovascular inflammation is an important step forward for the care of our patients," said Paul Ridker, MD, MPH, professor of medicine, Harvard Medical School and director of the Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, who has been instrumental in elucidating the role of inflammation in cardiovascular disease. Dr. Ridker added, "To treat coronary disease effectively, cardiologists must aggressively reduce inflammation and cholesterol. For appropriate patients already taking a statin, adding the anti-inflammatory drug colchicine at a dose of 0.5 mg daily has been proven to significantly lower risks of recurrent heart attack and stroke.""